Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03617679 · ClinicalTrials.gov registry record · Phase 2
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
A Phase 2 study of Metastatic Endometrial Cancer, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
- 1
- Study location
NCT03617679: Active Phase 2 study of Metastatic Endometrial Cancer, sponsored by University of Colorado, Denver.
NCT03617679 is a Phase 2 study of Metastatic Endometrial Cancer that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 79 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03617679, a Phase 2 study of Metastatic Endometrial Cancer, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to determine the effectiveness of Rucaparib as maintenance therapy for metastatic and recurrent endometrial cancer, after 1-2 prior lines of therapy.
Primary Outcome
Progression free survival is defined as cycle 1 day 1 (C1D1) till the time of progression as determined by RECIST 1.1 criteria or death.
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG Rucaparib
Study Locations (1)
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2019-03-06 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT03617679 still lists
NCT03617679 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Metastatic Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03617679 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT03617679 about?
NCT03617679 is a clinical study titled "Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer". This study seeks to determine the effectiveness of Rucaparib as maintenance therapy for metastatic and recurrent endometrial cancer, after 1-2 prior lines of therapy.
What is the current status of trial NCT03617679?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2019-03-06. Estimated completion is 2026-12.
What conditions does trial NCT03617679 study?
This clinical trial studies the following conditions: Metastatic Endometrial Cancer.
What interventions are being tested in trial NCT03617679?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT03617679?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03617679 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03617679's enrollment target sits among peer trials
79 884th of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI